Zacks: Analysts Expect Xencor Inc (XNCR) Will Post Earnings of -$0.25 Per Share
Equities analysts expect that Xencor Inc (NASDAQ:XNCR) will report earnings per share (EPS) of ($0.25) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Xencor’s earnings, with the lowest EPS estimate coming in at ($0.29) and the highest estimate coming in at ($0.19). Xencor reported earnings per share of $1.13 during the same quarter last year, which would suggest a negative year-over-year growth rate of 122.1%. The company is scheduled to report its next quarterly earnings report on Tuesday, August 1st.
According to Zacks, analysts expect that Xencor will report full year earnings of ($1.14) per share for the current fiscal year, with EPS estimates ranging from ($1.34) to ($0.92). For the next year, analysts expect that the business will post earnings of ($1.62) per share, with EPS estimates ranging from ($2.02) to ($1.15). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Xencor.
Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.06. Xencor had a negative net margin of 337.21% and a negative return on equity of 19.01%. The firm had revenue of $4.34 million for the quarter, compared to analyst estimates of $8.15 million.
Several research firms recently weighed in on XNCR. Wedbush reiterated an “outperform” rating and issued a $29.00 target price on shares of Xencor in a research note on Friday, June 16th. Zacks Investment Research cut shares of Xencor from a “buy” rating to a “hold” rating in a research note on Saturday, April 29th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Xencor has a consensus rating of “Buy” and a consensus price target of $28.67.
COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Expect Xencor Inc (XNCR) Will Post Earnings of -$0.25 Per Share” was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/07/20/zacks-analysts-expect-xencor-inc-xncr-will-post-earnings-of-0-25-per-share.html.
In related news, major shareholder John S. Stafford III bought 1,500 shares of Xencor stock in a transaction that occurred on Friday, June 16th. The stock was acquired at an average price of $19.67 per share, for a total transaction of $29,505.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder John S. Stafford III bought 6,000 shares of Xencor stock in a transaction that occurred on Wednesday, June 28th. The stock was bought at an average price of $19.94 per share, with a total value of $119,640.00. The disclosure for this purchase can be found here. In the last quarter, insiders sold 46,238 shares of company stock valued at $1,037,822. 4.03% of the stock is owned by corporate insiders.
Several large investors have recently added to or reduced their stakes in XNCR. Acadian Asset Management LLC boosted its position in shares of Xencor by 54.5% in the first quarter. Acadian Asset Management LLC now owns 322,768 shares of the biopharmaceutical company’s stock worth $7,722,000 after buying an additional 113,862 shares in the last quarter. Nationwide Fund Advisors boosted its position in shares of Xencor by 5.2% in the first quarter. Nationwide Fund Advisors now owns 58,084 shares of the biopharmaceutical company’s stock worth $1,389,000 after buying an additional 2,847 shares in the last quarter. Candriam Luxembourg S.C.A. boosted its position in shares of Xencor by 80.0% in the first quarter. Candriam Luxembourg S.C.A. now owns 135,000 shares of the biopharmaceutical company’s stock worth $3,229,000 after buying an additional 60,000 shares in the last quarter. Creative Planning boosted its position in shares of Xencor by 2.7% in the first quarter. Creative Planning now owns 38,400 shares of the biopharmaceutical company’s stock worth $919,000 after buying an additional 1,000 shares in the last quarter. Finally, Teachers Advisors LLC boosted its position in shares of Xencor by 2.0% in the fourth quarter. Teachers Advisors LLC now owns 319,914 shares of the biopharmaceutical company’s stock worth $8,420,000 after buying an additional 6,392 shares in the last quarter. Institutional investors and hedge funds own 75.00% of the company’s stock.
Shares of Xencor (NASDAQ XNCR) traded down 2.62% during mid-day trading on Thursday, reaching $23.00. The company’s stock had a trading volume of 184,706 shares. Xencor has a 12 month low of $18.10 and a 12 month high of $29.38. The stock has a market capitalization of $1.07 billion, a P/E ratio of 65.16 and a beta of 2.13. The company has a 50 day moving average price of $21.71 and a 200 day moving average price of $23.23.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xencor Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc and related companies with MarketBeat.com's FREE daily email newsletter.